Fig. 1

NE and MPO in stroke patients versus controls. Stroke patients were analysed and compared to healthy controls. MPO and NE levels were measured intracellularly in granulocytes by flow cytometry (a, c) and are reported as MFI and in the sera of patients using ELISA (b, d) and reported in ng/ml. MPO was estimated on the day of stroke admission (d0), day 1 (d1), day 3 (d3) and day 5 (d5) by flow cytometry (a; n _crtl = 14, n _d0 = 14, n _d1 = 18, n _d3 = 14, n _d5 = 15). The extracellular amount of MPO was measured by ELISA (d0, d1, d3, d5) (b; n _crtl = 11, n _d0 = 8, n _d1 = 12, n_d3 = 18, n _d5 = 17). The intracellular amount of NE was measured on the day after stroke (d1) and on days 3 and 5 (d3, d5) (c, n _crtl = 10, n _d1 = 10, n _d3 = 10, n _d5 = 10). NE in the sera was analysed on the day of stroke admission (d0) and on days 1, 3 and 5 after stroke (d1, d3, d5) (d; n _crtl = 11, n _d0 = 8, n _d1 = 12, n _d3 = 18, n _d5 = 17). *p < 0.05; **p < 0.01; ***p < 0.005. Mean and SD ranges for a and c and medians and interquartile ranges for b and d are given. ANOVA and Bonferroni comparisons as post hoc tests were used for data in a and c; data in b and d were assessed by Kruskal–Wallis test and Dunn’s multiple comparison test